BioDiem

DEVELOPING COMMERCIAL OUTCOMES

CEO AGM 2025 Presentation

Julie Phillips | CEO and Director, BioDiem Ltd



SAFE HARBOUR STATEMENT

This presentation is provided to you for information purposes only and should not be construed as investment advice or an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in BioDiem Limited ("BioDiem"), or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in BioDiem will be entered into on the basis of this presentation.

This presentation contains forward-looking statements which are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, at the date this presentation was prepared, are expected to take place. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of BioDiem. BioDiem cannot and does not give any assurance that the results, performance or achievements expressed or implied by the forward looking statements contained in this presentation will actually occur and you should not place reliance on these forward looking statements.

To the maximum extent permitted by applicable laws, BioDiem and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of BioDiem.

FY2025 Highlights

BioDiem

Income from milestone payments totalling $423,439 (2023: $394,978)

Divestment of Opal Biosciences Ltd (November 2024) $105,070 received

Shareholder approval of new class of Convertible Preference Share. The CPS 2024 issue raised $127,501.

DEVELOPING COMMERCIAL OUTCOMES

Events after the reporting period

BioDiem

5 August 2025:
Licence Variation and Tech Transfer Agreements signed with BCHT
- US$3,142,986 received to date with further funds to come

Payout of the 2024 Convertible Preference Shares in full
(Total: $225,000)

Ongoing commercial discussions for LAIV sale/licence

DEVELOPING COMMERCIAL OUTCOMES

Changchun BCHT Biotechnology Co

BioDiem

Changchun BCHT Biotechnology Co. (SHA:688276)

China · Delayed Price · Currency is CNY

19.31 +0.10 (0.52%)

At close: Dec 19, 2025

Overview | Financials | Statistics | Dividends | History | **Profile** | Chart

Profile | Employees

Changchun BCHT Biotechnology Co. Company Description

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally.

The company's products include herpes zoster vaccine; varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and rabies vaccine (vero cell) for humans.

Changchun BCHT Biotechnology Co. Ltd. was founded in 2004 and is based in Changchun, China.

DEVELOPING COMMERCIAL OUTCOMES

ELSEVIER

Vaccine

Volume 46, 6 February 2025, 126653



Immunogenicity and safety of live attenuated influenza vaccine in children aged 3–17 years in China

Lizhe Ai [a], Zhao Gao [b], Huakun Lv [c], Jikai Zhang [d], Na Xu [e], Hui Zhao [f], Qiang Lu [e], Hongcai Zhu [e], Nianmin Shi [e], Wei Wei [e], Dawei Liu [e], Qiong Yu [a]

ELSEVIER

Vaccine

Volume 59, 20 June 2025, 127268



Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial

Xiaoling Tian [a 1], Yiguo Zhou [b c 1], Peng Deng [d 1], Na Xu [e], Xiaojun Liu [f], Ying Guo [g], Aimin Fang [h], Pingping Liu [i], Yi Yan [f], Lu Yang [a], Binge Qian [h], Yuxin Lu [a], Ying Chen [a], Yang Zang [e], Qin-Yi Ma [j], Juan Du [j], Mengmeng Li [k] ✉, Beifang Yang [d] ✉, Qiang Lu [e] ✉, Qing-Bin Lu [c j l] ✉

Changchun BCHT Biotechnology Co

BioDiem

LAIV Development timeline summary

2012:	Licence from BioDiem Ltd for LAIV sales in China (private market; egg-based vaccine product)
2020:	Launch of LAIV intranasal flu vaccine for children 3-17 years
2025:	Variation of Licence to include cell-based vaccine product and establishment of vaccine reassortant manufacturing facility in China for use in future production
2026 (est.):	Completion of payments Direct assignment of the varied rights from BioDiem to BCHT.

Serum Institute of India

BioDiem

SERUM INSTITUTE OF INDIA
Cyrus Poonawalla Group

NASOVAC-S4

Influenza Vaccine (Human, Live Attenuated) I.P.
Seasonal, Quadrivalent (Liquid) Intranasal

INDICATION
Indicated in individuals above 2 years of age.

ROUTE OF ADMINISTRATION
For administration by intranasal spray.

Video of Administration Process of Nasovac-S4

DOSAGE
A single intranasal dose of 0.5 ml is administered as 0.25 ml per nostril.

PRESENTATION:
1 dose vial (0.5 ml) Intranasal

Serum Institute of India

BioDiem

Serum Life Sciences

SERUM INSTITUTE OF INDIA
Cyrus Poonawalla Group

SERUM INSTITUTE OF INDIA PVT. LTD.
Cyrus Poonawalla Group

Bilthoven Biologicals
Cyrus Poonawalla Group



Board & Management

BioDiem

Chairman		Mr Damien Hannes
CEO & Director		Ms Julie Phillips
Executive Director		Prof Larisa Rudenko
Company Secretary		**Mr Stefan Ross**



Capital structure

BioDiem

Shares on Issue		No. of shares
Ordinary Shares		174,734,060
2016 Preference shares		14,392,433
2024 Preference shares*		1,593,750*
* Paid out in September 2025		

Outlook for FY26

LAIV

Finalise discussions re outlicence and technology assignment and sale

BioDiem

DEVELOPING COMMERCIAL OUTCOMES

Thank you for your attendance